How much cash does Palvella Therapeutics generate?

Palvella Therapeutics (PVLA) generated -$29.1M in operating cash flow over the trailing twelve months.

What is Palvella Therapeutics's free cash flow?

Palvella Therapeutics's free cash flow was -$15.2M over the trailing twelve months, up 67.1% year over year.

Where does Palvella Therapeutics's cash flow data come from?

Every line is extracted from Palvella Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Palvella Therapeutics PVLA Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$49.3M-18.2%	-$41.72M-19.0%	-$35.07M-31.8%	-$26.61M-28.4%	-$20.73M-37.5%
Stock-based compensation	$8.68M+35.7%	$6.4M+39.6%	$4.59M+53.1%	$2.99M+68.4%	$1.78M+114%
Change in accounts payable	——	——	——	$2.97M-9.4%	$3.28M+46.4%
Change in accrued liabilities	——	——	——	——	——
Change in other assets	-$188K+86.2%	-$1.36M-1,256%	$118K-72.8%	$434K-41.2%	$738K-50.9%
Loss on extinguishment of debt	——	——	——	——	——
Change in operating lease liabilities	——	——	——	——	——
Net cash from operating activities	-$29.1M-16.4%	-$25.01M+1.8%	-$25.47M-25.3%	-$20.34M-23.2%	-$16.51M-52.3%
Net cash from investing activities	——	——	——	——	——
Proceeds from issuance of common stock	$230.76M+30,144%	$763K+16.0%	$658K+58.2%	$416K—	$0—
Other financing activities	——	——	——	——	——
Payment of debt issuance costs	——	——	——	——	——
Net cash from financing activities	——	——	——	——	$85.89M-1.4%
Effect of exchange rate changes on cash	——	——	$659K+694%	-$111K-3,600%	-$3K-200%
Net increase (decrease) in cash	$130.77M+610%	-$25.62M-152%	$49.36M-12.2%	$56.23M-19.3%	$69.71M-9.0%
Accretion (Amortization) of Discounts and Premiums, Investments	——	——	——	——	——
Accounts payable	——	——	——	$2.97M-9.4%	$3.28M+46.4%
Accrued expenses and other liabilities	——	——	——	——	——
Increase Decrease In Derivative Liabilities	$435K+10.4%	$394K-21.8%	$504K+1.4%	$497K-23.5%	$650K+2.7%
Operating lease liabilities	——	——	——	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	-$188K+86.2%	-$1.36M-1,256%	$118K-72.8%	$434K-41.2%	$738K-50.9%
Payments Of Stock Issuance Costs	——	$154K+33.3%	$115.5K+50.0%	$77K+100%	$38.5K—
Cash Acquired From Reverse Merger Transaction	——	$0-100%	$3.45M-50.0%	$6.9M-33.3%	$10.35M-25.0%
Increase Decrease In Operating Lease Liability	——	——	——	——	——
Increase Decrease In Research And Development Tax Credit Receivables	——	-$2.11M-94.1%	-$1.08M-1,607%	-$63.5K-107%	$957.25K-51.6%
Non Cash Lease Operating Expense	——	——	——	——	$0—
Noncash Interest Expense Income Royalty Agreement	——	——	——	——	$4.13M+6.3%
Payment For Contingent Consideration Liability Financing Activities	——	——	——	——	——
Payments Of Merger Related Costs Financing Activities	——	——	——	——	$3.74M+51.3%
Payments Of Transaction Costs Associated With Pipe Financing	——	$0-100%	$635.5K-50.0%	$1.27M-33.3%	$1.91M-25.0%
Transaction Costs Related To Reverse Merger Included In Accounts Payable And Accrued Expenses	——	$0-100%	$317.25K-50.0%	$634.5K-33.3%	$951.75K-25.0%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Palvella Therapeutics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does Palvella Therapeutics generate?: Palvella Therapeutics (PVLA) generated -$29.1M in operating cash flow over the trailing twelve months.
What is Palvella Therapeutics's free cash flow?: Palvella Therapeutics's free cash flow was -$15.2M over the trailing twelve months, up 67.1% year over year.
Where does Palvella Therapeutics's cash flow data come from?: Every line is extracted from Palvella Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.